Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review

Detalhes bibliográficos
Autor(a) principal: Ferreira, Mario Henrique Quim
Data de Publicação: 2017
Outros Autores: Ribeiro, Rodrigo Metzker Pereira, Funes, Ana Beatriz Antunes, Faustino, Bruna Mohine Oliveira, Segato, Fernanda Cardin, Mattos, Luana Lozano Cardoso de, Carvalho, Thais Caroline dos Santos, Prada Filho, Carlos Funes
Tipo de documento: Artigo
Idioma: por
Título da fonte: Revista de Atenção à Saúde
Texto Completo: http://seer.uscs.edu.br/index.php/revista_ciencias_saude/article/view/4439
Resumo: Introduction: The hypercholesterolemia can lead to conditions such as acute myocardial infarction (AMI). However, cholesterol elevation is not always caused by poor diet habits and lifestyle; groups such as familial hypercholesterolemia (HF) have serum values increased by genetic alterations, and traditional dyslipidemic medications are not effective enough for these peoples. Objective: To compile and discuss the results obtained by the current literature that focuses on the evolocumab monoclonal antibody to decrease PCSK9 levels. Materials and methods: Systematic review of the results of tests done with humans over 19 years of age, published in the last 5 years in the English language, using the PubMed database. Results: 135 articles were found, and nine studies were selected by exclusion criteria. Discussion: Results demonstrated that the pharmacological power of the evolocumab antibody has a remarkable value compared to the usual therapies and placebo for patients who did not show great response to current therapies. Conclusion: This is a very recent study, which requires further research to show possible adverse reactions and interactions with other drugs. However, so far it has demonstrated a great advantage for future treatments because it occupies a place not previously filled by traditional pharmacology.
id USCS-3_d3cba65fa105d63c9fc49b15760d2cd2
oai_identifier_str oai:ojs2.seer.uscs.edu.br:article/4439
network_acronym_str USCS-3
network_name_str Revista de Atenção à Saúde
repository_id_str
spelling Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic reviewAtividade terapêutica do anticorpo monoclonal evolocumab contra proteínas PCSK9 na modulação do colesterol LDL: revisão sistemáticaHiperlipoproteinemia tipo IILipoproteínas LDLInfarto do miocárdioPCSK9Hyperlipoproteinemia type IILDL lipoproteinsMyocardial infarctionPCSK9Introduction: The hypercholesterolemia can lead to conditions such as acute myocardial infarction (AMI). However, cholesterol elevation is not always caused by poor diet habits and lifestyle; groups such as familial hypercholesterolemia (HF) have serum values increased by genetic alterations, and traditional dyslipidemic medications are not effective enough for these peoples. Objective: To compile and discuss the results obtained by the current literature that focuses on the evolocumab monoclonal antibody to decrease PCSK9 levels. Materials and methods: Systematic review of the results of tests done with humans over 19 years of age, published in the last 5 years in the English language, using the PubMed database. Results: 135 articles were found, and nine studies were selected by exclusion criteria. Discussion: Results demonstrated that the pharmacological power of the evolocumab antibody has a remarkable value compared to the usual therapies and placebo for patients who did not show great response to current therapies. Conclusion: This is a very recent study, which requires further research to show possible adverse reactions and interactions with other drugs. However, so far it has demonstrated a great advantage for future treatments because it occupies a place not previously filled by traditional pharmacology.Introdução: As alterações de hipercolesterolemia podem gerar patologias como o infarto agudo do miocárdio (IAM). No entanto, nem sempre o aumento do colesterol é ocasionado apenas pela má alimentação e pelo estilo de vida; grupos como o da hipercolesterolemia familiar (HF) têm valores séricos aumentados por alterações genéticas e, nesses casos, as medicações antidislipidemiantes tradicionais não são eficazes. Objetivo: Compilar e discutir os resultados obtidos pela literatura atual que se debruça sobre o anticorpo monoclonal evolocumab para diminuição do PCSK9. Materiais e métodos: Revisão sistemática dos resultados de testes feitos em humanos com idade superior a 19 anos publicados em língua inglesa há menos de cinco anos, utilizando a base de dados PubMed. Resultados:Foram encontrados 135 artigos, dentre os quais nove foram selecionados por critérios de exclusão. Discussão: Os resultados demonstraram que o poder farmacológico do anticorpo evolocumab tem notória valia diante de terapêuticas habituais e placebos para pacientes que não apresentam resposta significativa com as terapias atuais. Conclusão: Por se tratar de um estudo bastante recente, ainda há necessidade de mais pesquisas que demonstrem eventuais reações adversas e interações com outros medicamentos. No entanto, já está em evidência uma grande vantagem para tratamentos futuros por preencher lacunas da farmacologia tradicional.Universidade Municipal de São Caetano do Sul - USCS2017-08-17info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionArtigo de Revisãoapplication/pdfhttp://seer.uscs.edu.br/index.php/revista_ciencias_saude/article/view/443910.13037/ras.vol15n52.4439Journal of Health Care; Vol. 15 No. 52 (2017); 72-77Revista de Atenção à Saúde; v. 15 n. 52 (2017); 72-772359-4330reponame:Revista de Atenção à Saúdeinstname:Universidade Municipal de São Caetano do Sul (USCS)instacron:USCSporhttp://seer.uscs.edu.br/index.php/revista_ciencias_saude/article/view/4439/pdfFerreira, Mario Henrique QuimRibeiro, Rodrigo Metzker PereiraFunes, Ana Beatriz AntunesFaustino, Bruna Mohine OliveiraSegato, Fernanda CardinMattos, Luana Lozano Cardoso deCarvalho, Thais Caroline dos SantosPrada Filho, Carlos Funesinfo:eu-repo/semantics/openAccess2017-08-18T22:32:36Zoai:ojs2.seer.uscs.edu.br:article/4439Revistahttps://seer.uscs.edu.br/index.php/revista_ciencias_saudePUBhttp://seer.uscs.edu.br/index.php/revista_ciencias_saude/oaieditoria.ras@online.uscs.edu.br || vera.basso@online.uscs.edu.br2359-43302359-4330opendoar:2017-08-18T22:32:36Revista de Atenção à Saúde - Universidade Municipal de São Caetano do Sul (USCS)false
dc.title.none.fl_str_mv Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review
Atividade terapêutica do anticorpo monoclonal evolocumab contra proteínas PCSK9 na modulação do colesterol LDL: revisão sistemática
title Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review
spellingShingle Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review
Ferreira, Mario Henrique Quim
Hiperlipoproteinemia tipo II
Lipoproteínas LDL
Infarto do miocárdio
PCSK9
Hyperlipoproteinemia type II
LDL lipoproteins
Myocardial infarction
PCSK9
title_short Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review
title_full Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review
title_fullStr Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review
title_full_unstemmed Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review
title_sort Therapeutic action of the evolocumab monoclonal antibody against PCSK9 proteins in LDL cholesterol modulation: systematic review
author Ferreira, Mario Henrique Quim
author_facet Ferreira, Mario Henrique Quim
Ribeiro, Rodrigo Metzker Pereira
Funes, Ana Beatriz Antunes
Faustino, Bruna Mohine Oliveira
Segato, Fernanda Cardin
Mattos, Luana Lozano Cardoso de
Carvalho, Thais Caroline dos Santos
Prada Filho, Carlos Funes
author_role author
author2 Ribeiro, Rodrigo Metzker Pereira
Funes, Ana Beatriz Antunes
Faustino, Bruna Mohine Oliveira
Segato, Fernanda Cardin
Mattos, Luana Lozano Cardoso de
Carvalho, Thais Caroline dos Santos
Prada Filho, Carlos Funes
author2_role author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Ferreira, Mario Henrique Quim
Ribeiro, Rodrigo Metzker Pereira
Funes, Ana Beatriz Antunes
Faustino, Bruna Mohine Oliveira
Segato, Fernanda Cardin
Mattos, Luana Lozano Cardoso de
Carvalho, Thais Caroline dos Santos
Prada Filho, Carlos Funes
dc.subject.por.fl_str_mv Hiperlipoproteinemia tipo II
Lipoproteínas LDL
Infarto do miocárdio
PCSK9
Hyperlipoproteinemia type II
LDL lipoproteins
Myocardial infarction
PCSK9
topic Hiperlipoproteinemia tipo II
Lipoproteínas LDL
Infarto do miocárdio
PCSK9
Hyperlipoproteinemia type II
LDL lipoproteins
Myocardial infarction
PCSK9
description Introduction: The hypercholesterolemia can lead to conditions such as acute myocardial infarction (AMI). However, cholesterol elevation is not always caused by poor diet habits and lifestyle; groups such as familial hypercholesterolemia (HF) have serum values increased by genetic alterations, and traditional dyslipidemic medications are not effective enough for these peoples. Objective: To compile and discuss the results obtained by the current literature that focuses on the evolocumab monoclonal antibody to decrease PCSK9 levels. Materials and methods: Systematic review of the results of tests done with humans over 19 years of age, published in the last 5 years in the English language, using the PubMed database. Results: 135 articles were found, and nine studies were selected by exclusion criteria. Discussion: Results demonstrated that the pharmacological power of the evolocumab antibody has a remarkable value compared to the usual therapies and placebo for patients who did not show great response to current therapies. Conclusion: This is a very recent study, which requires further research to show possible adverse reactions and interactions with other drugs. However, so far it has demonstrated a great advantage for future treatments because it occupies a place not previously filled by traditional pharmacology.
publishDate 2017
dc.date.none.fl_str_mv 2017-08-17
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
Artigo de Revisão
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://seer.uscs.edu.br/index.php/revista_ciencias_saude/article/view/4439
10.13037/ras.vol15n52.4439
url http://seer.uscs.edu.br/index.php/revista_ciencias_saude/article/view/4439
identifier_str_mv 10.13037/ras.vol15n52.4439
dc.language.iso.fl_str_mv por
language por
dc.relation.none.fl_str_mv http://seer.uscs.edu.br/index.php/revista_ciencias_saude/article/view/4439/pdf
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Municipal de São Caetano do Sul - USCS
publisher.none.fl_str_mv Universidade Municipal de São Caetano do Sul - USCS
dc.source.none.fl_str_mv Journal of Health Care; Vol. 15 No. 52 (2017); 72-77
Revista de Atenção à Saúde; v. 15 n. 52 (2017); 72-77
2359-4330
reponame:Revista de Atenção à Saúde
instname:Universidade Municipal de São Caetano do Sul (USCS)
instacron:USCS
instname_str Universidade Municipal de São Caetano do Sul (USCS)
instacron_str USCS
institution USCS
reponame_str Revista de Atenção à Saúde
collection Revista de Atenção à Saúde
repository.name.fl_str_mv Revista de Atenção à Saúde - Universidade Municipal de São Caetano do Sul (USCS)
repository.mail.fl_str_mv editoria.ras@online.uscs.edu.br || vera.basso@online.uscs.edu.br
_version_ 1798042262039429120